Sanofi

Alexey Rak

Francis Blanche

Béatrice Cameron

Hervé Bouchard

Tarik Dabdoubi

Stéphanie Decary

Paul Ferrari

Pierre-Francois Berne

Herve Bouchard

Beatrice Cameron

Nicolas Baurin

Han Li

Dorothea Kominos

Philip Janiak

Magali Mathieu

Alla Pritsker

Bruno Poirier

Francis Duffieux

Cyril Daveu

Patrick Grailhe

Christopher Ryan Morgan

Pierre-François Berne

Disclosed are antibodies which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Anti-CEACAM5 antibodies and uses thereof

Antibodies are provided which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

The present invention discloses antibodies which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

Growing community of inventors

Paris, France

Alexey Rak